The launch of JHP GENERICS is the result of JHP’s focus on meeting customer needs for an affordable and reliable supply of high quality products. The generic division will leverage JHP’s established infrastructure in development, manufacturing, marketing and distribution, and will concentrate on the acute care market, which has been challenged by product shortages in recent years.

Stuart Hinchen, President and CEO of JHP Pharmaceuticals commented, “The initial generic portfolio, which are all currently available for purchase, has a range of products in a variety of therapeutic areas including Anesthesiology, Gastroenterology, Infectious Disease and Women’s Healthcare, and totals 13 product SKU’s. Additionally, we have a strong pipeline with several new products launching throughout the course of 2013 and beyond. These products will contribute toward addressing market shortages in acute care and oncology segments.”

The introduction of JHP’s generic division is part of a strategy to expand the business through the establishment of additional growth platforms. Hinchen added, “JHP already has a very successful arm marketing a range of brand products and a growing Contract Manufacturing business. We continue to actively market our brand name products including Aplisol®, Brevital® and Dantrium®. Further, we have made investments over the past several years to expand capacity in our cGMP-compliant, Rochester Michigan facility, to support growth in JHP labeled products and provide enhanced benefit to our expanding Contract Manufacturing customer base. We are well poised to support future growth, fueled by a robust pipeline, and look forward to providing an affordable and reliable supply of high quality products through the formation of this new generic division.”

About JHP Pharmaceuticals, LLC

JHP Pharmaceuticals, headquartered in New Jersey, is a fully integrated specialty Pharmaceutical company that acquires, develops, manufactures and sells sterile injectable products. JHP’s sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse. JHP employs more than 370 staff in the USA in its manufacturing, product development, sales & marketing and corporate areas. For more information, please visit www.jhppharma.com.

Additional Press Releases

04/17/13 JHP Pharmaceuticals To Produce Supplies of Biologic Drug Product For Late-Phase Clinical Trials Webpage  |  PDF Format 12/31/12 JHP Pharmaceuticals Acquired By Warburg Pincus Webpage  |  PDF Format 09/19/12 JHP Pharmaceuticals To Produce Lyophilized Biologic for International Late-Phase Clinical Trials Webpage  |  PDF Format 06/07/12 JHP Pharmaceuticals Launches Generic Division Webpage  |  PDF Format 06/05/12 JHP Pharmaceuticals to Produce Clinical and Commercial Supply of an Innovative Injectable Webpage  |  PDF Format

02/29/12 JHP Pharmaceuticals Adds Second Product To Multi-Year Contract Manufacturing Agreement Webpage  |  PDF Format

10/18/11 JHP Pharmaceuticals Enters Agreement to Produce Diagnostic Aid Webpage  |  PDF Format

07/25/11 JHP Pharmaceuticals to Produce Clinical Batches of Innovative Cardiac Drug Webpage  |  PDF Format

07/06/11 JHP Pharmaceuticals Enters Agreement To Produce Life-Saving Drug Webpage  |  PDF Format

07/05/11 JHP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin® Webpage  |  PDF Format

06/24/11 JHP Pharmaceuticals Announces Chief Executive Officer Succession Webpage  |  PDF Format

03/28/11 JHP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement Webpage  |  PDF Format

02/24/11 JHP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement Webpage  |  PDF Format

01/27/11 JHP Pharmaceuticals & Putney Inc. Announce Multi-Year Contract Manufacturing Agreement Webpage  |  PDF Format

06/29/10 JHP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement Webpage  |  PDF Format

05/10/10 JHP Pharmaceuticals Announces Successful Completion of FDA and EMEA GMP Audits Webpage  |  PDF Format

09/28/09 JHP Announces FDA Approval for Dantrium IV, rapidly mixing in 20 seconds Webpage  |  PDF Format

08/20/08 JHP Pharmaceuticals & SpePharm complete purchaseof Dantrium® (dantrolene sodium) Webpage  |  PDF Format

07/16/07 King Pharmaceuticals Completes Sale Of Rochester, Michigan Manufacturing Facility To JHP Pharmaceuticals Webpage  |  PDF Format

Return To Press Releases »